Answers are grounded in this paper and cite their sources.
Sir, Ceftaroline is the active metabolite of the cephalosporin prodrug ceftaroline fosamil. With in vitro activity and clinical efficacy against MRSA due to its high affinity for PBP2a,1 it is approved for the treatment of complicated acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia. Reduced ceftaroline susceptibility has been associated with PBP2a alterations conferring reduced drug affinity.2 We assessed the in vitro activity of ceftaroline against MRSA strains isolated in our teaching hospital laboratory, prior to the introduction of the drug to the hospital formulary or any substantial use in our geographical region. Consecutive MRSA isolates from clinical and infection control screening specimens on unique patients were prospectively collected between August and December 2013. Susceptibility testing was performed by both EUCAST3 and CLSI4 disc diffusion testing methods. CLSI and EUCAST ceftaroline disc diffusion testing were performed on Mueller–Hinton agar (MHA) and ceftaroline MICs were determined by gradient diffusion (Etest, Oxoid, UK) on MHA. Broth microdilution (BMD) testing was performed in accordance with CLSI guidelines using pure ceftaroline powder, obtained from AstraZeneca Australia, in triplicate.
No takes yet. Share an insight, caveat, or question.
Mubarak et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: